BJL
AKBA icon

Brighton Jones LLC’s Akebia Therapeutics AKBA Stock Holding History

Brighton Jones LLC’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.4K Buy
+19,650
New +$23.4K ﹤0.01% 1395

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
CL
Choreo LLC Rockford, Illinois $9.11B AUM 26.3% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VEA
Virtus ETF Advisers New York $261M AUM 78.99% 1-Year Est. Return

Brighton Jones LLC's AKBA Position: Q2 2026 in Review

Brighton Jones LLC opened a new position in Akebia Therapeutics (AKBA) in Q2 2026: 19,650 shares worth $22.4K. The stake represents ﹤0.01% of the portfolio and ranks #1395 among its holdings.

82 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Brighton Jones LLC held 19,650 shares of Akebia Therapeutics worth $22.4K as of Q2 2026.
  • Akebia Therapeutics was a new Brighton Jones LLC position in Q2 2026.
  • Akebia Therapeutics made up ﹤0.01% of Brighton Jones LLC's portfolio in Q2 2026, its #1395 holding.
  • 82 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Brighton Jones LLC's 13F filing for Q2 2026, filed 11 Aug 2026.